Outsourcing

Jun 15, 2016
BioPharm International
By BioPharm International Editors
Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.
Jun 15, 2016
BioPharm International
By BioPharm International Editors
Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
Jun 10, 2016
By BioPharm International Editors
Brammer Bio establishes late-phase development and commercial manufacturing facility for advanced cell and gene therapies in Lexington, MA.
Jun 07, 2016
Uncertainty about the demand for a biologic medication can be partly mollified with some well-planned capacity outsourcing, contends a new report by ORC International sponsored by Patheon.
Jun 07, 2016
By BioPharm International Editors
The new company is the product of a merger with Formex.
Jun 02, 2016
BioPharm International
Acquisition binges often lead to hangovers; here’s what to watch out for.
May 31, 2016
BioPharm sat down with an intellectual property lawyer to examine how companies are protected when they engage in activities where sharing of trade secrets must occur.
May 01, 2016
BioPharm International
Growth may be slowing, but outsourcing activity remains healthy.
Apr 01, 2016
Contract biopharmaceutical manufacturing has been growing steadily and is expected to reach $4.1 billion by 2019.
Apr 01, 2016
BioPharm International
Demand is driving expansion and consolidation of formulation and clinical trial materials services.
native1_300x100
lorem ipsum